BioSpace News Archive

Ocean Biomedical, Inc. Virion Therapeutics, LLC recently presented highly compelling preclinical oncology data at the annual meeting of the Society for Immunotherapy of Cancer, SITC 2023.

The National Institutes of Health has awarded $1.1 million to a team led by Worcester Polytechnic Institute researcher Ulkuhan Guler to develop a first-of-its-kind wearable sensor for premature infants that will address racial bias in healthcare by monitoring oxygen levels two different ways and correcting the measurements to account for variations in skin color.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

MDxHealth SA, a commercial-stage precision diagnostics company, announced that Michael K. McGarrity, Chief Executive Officer, will participate in a fireside chat at the 35th Piper Sandler Healthcare Conference on Wednesday, November 29, 2023, at 9:00am ET.

PHAXIAM Therapeutics, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, provides a business and financial update for the third quarter of 2023.

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, New York.

STRATA Skin Sciences, Inc. announced financial results for the third quarter ended September 30, 2023.

Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2023, and provided a corporate update.